In this task, you are given a passage which has a question and the context. You have to generate an answer to the question based on the information present in the context.
--------
Question: Context: Patients with diabetes are at increased risk of ischemic events. Suv39h1 is a histone methyltransferase that catalyzes the methylation of histone 3 lysine 9, which is associated with the suppression of inflammatory genes in diabetes. However, the role of Suv39h1 in myocardial ischemia/reperfusion (I/R) injury under diabetic condition has not been evaluated.', 'To generate diabetic model, male SD rats were fed with 60% fat diet followed by intraperitoneal injection with 40mg/kg streptozotocin. Adenovirus encoding Suv39h1 gene was used for Suv39h1 overexpression. Each rat received injections of adenovirus at five myocardial sites. Three days after gene transfection, each rat was subjected to left main coronary artery occlusion and reperfusion. After 30 min ischemia and reperfusion for 4 h, the rats were euthanized for real-time PCR, Western blot, immunohistochemical staining, and morphometric analysis.', 'Delivery of Ad-Suv39h1 into the hearts of diabetic rats could markedly increase Suv39h1 expression. Up-regulation of Suv39h1 significantly reduced infarct size and tissue damage after I/R injury, which was associated with protection from apoptosis of cardiac myocytes and reduction of inflammatory response. In addition, compared with injury group, Ad-Suv39h1 led to a decreased activity of mitogen-activated protein kinase family and its down-steam transcriptional factor NF-κB.\Question: Does suv39h1 protect from myocardial ischemia-reperfusion injury in diabetic rats?

Answer: Overexpression of Suv39h1 results in the de-activation of proinflammatory pathways and reduced apoptosis and myocardial injury. Therefore, Suv39h1 might represent a novel therapeutic strategy to reduce I/R injury under diabetic condition.


Question: Context: To determine the role of recipient lymphopenia state in the expansion and function of leukemia specific cytotoxic T lymphocytes (CTLs).', 'C57BL/6 mice were induced to lymphopenia with 6 Gy total body irradiation. Spleen T cells or leukemia specific T cells from EGFP+ transgenic C57BL/6-EGFP mice were adoptively transferred by intravenous injection. The mice were challenged subcutaneously with 1 x 10(6) FBL3 leukemic cells at day 2 after irradiation. The peripheral WBC count, percentage of EGFP+ cells, subsets of T cells and tumor sizes were monitored.', 'Both of the spleen T cell and leukemia specific CTL proliferated efficiently with the percentage of EGFP+ cells of 28. 81% and 42.24%, respectively, after infused into lymphopenic recipients. However, spleen T cells had no anti-leukemia effect regardless of its expansion. In contrast, leukemia specific CTLs showed a more rapid and extensive expansion under the condition of lymphopenia and a enhanced anti-leukemia immunity.\Question: Does [ Recipient lymphopenia state enhance the expansion and anti-leukemia effect of leukemia specific cytotoxic T lymphocytes ]?

Answer: Transfusion of leukemia specific CTLs under lymphopenia state could be a feasible strategy to expand leukemia specific CTLs and generate favorable anti-leukemia effect in vivo.


Question: Context: Cochrane Oral Health Group's Trials Register, CENTRAL, Medline via PubMed and EMBASE; no restrictions on language, published before February 1st 2013.", 'Observational studies reporting outcomes from irradiated and non-irradiated patients were eligible for inclusion as were randomised controlled trials (RCTs) and controlled clinical trials (CCTs) assessing irradiated patients submitted to different implant-based treatment protocols.', "Screening of titles, abstracts and full texts was by two reviewers, with disagreements resolved through discussion, consensus, or failing this by consultation with a third reviewer. Data extraction was in duplicate and attempts were made to contact authors for missing data. Risk of bias was assessed using adapted versions of the Cochrane Collaboration's tool (for RCTs and CCTs) and the Newcastle-Ottawa scale for observational studies.", 'Fifteen trials with 10,150 implants were included with 1,689 (14.3%) placed in irradiated mouths. There were 13 case series and two RCTs. three of the studies were on hyperbaric oxygen (HBO) therapy. Neither of the RCTs was rated as low risk of bias. Mean survival rates ranged from 46.3% to 98% with pooled estimates showing that implant failure was statistically significantly higher in irradiated patients compared to patients who had not undergone radiotherapy (an increase of 174%) with a risk ratio of 2.74 (95% confidence interval {CI}: 1.86, 4.05; p<0.00001). In maxillary sites, the risk ratio was 5.96 (95% CI:2.71, 13.12;p<0.00001) with the risk of loss increasing to 496%. Hyperbaric oxygen therapy did not reduce the risk of implant failure showing a risk ratio of 1.28 (95% CI:0.19, 8.82).\Question: Do radiotherapy associated with higher rates of dental implant loss?

Answer:
Irradiation of the head was linked to increased failure rate of implants compared to failure rates in patients who had not undergone radiotherapy. The failure rate was higher in the maxilla and HBO therapy did not improve implant survival.